Judge Agrees in Healthpoint's Favor
SAN ANTONIO, Texas - A federal judge has issued an order in favor of Healthpoint, Ltd., in a civil suit involving the infection prevention company and Ethex Corporation.
The marketing of Ethex products was the cause of litigation.
Reportedly, judge said "Ethex made a deliberate choice to make representations about its products that were false, knowing that such representations would cause substantial injury to Healthpoint."
Healthpoint officials initially alleged Ethex officials of marketing their product Ethexyme as a generic and alternative option in lieu of Healthpoint's prescription ointment Accuzyme. They also alleged Ethex officials marketed the two products had the same ingredients, when in fact they did not.
On this matter, the judge said, "Ethex's statement that Ethexyme had the `same ingredients in the same quantities' as Accuzyme was literally false."
H. Paul Dorman, chairman and CEO of Healthpoint, says such terms are devious.
"Such false statements led hospitals, pharmacies and other institutions to substitute Ethexyme for Accuzyme," he says. "The jury and judge have reinforced emphatically that patients should not be subjected to the inherent dangers associated with improper substitution."
For more information, visit: www.healthpoint.com.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
